TORONTO, Dec. 19 /CNW/ - Tm Bioscience Corporation (Toronto, Ontario;
TSX: TMC), a leader in the commercial genetic testing market, today announced
that it has closed its previously announced offering of 5,600,000 common
shares for gross proceeds of CDN $10,080,000.
The underwriting syndicate, led by Canaccord Capital Corp. and including
Versant Partners Inc. and Westwind Partners Inc., agreed to purchase 5,600,000
common shares from Tm Bioscience, on a bought deal basis, and sell them to the
public at a price of $1.80 per common share, representing an aggregate issue
amount of $10,080,000. As of the date hereof, after the closing, the Company
has 47,715,224 common shares issued and outstanding.
Net proceeds from the offering will be used for the advancement of Tm
Bioscience's pipeline of genetic tests for genetic disorders, drug metabolism
and infectious diseases, and for general working capital purposes.
